FDA Approves Pfizer’s Anti-smoking Drug

by Medindia Content Team on  May 12, 2006 at 4:41 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

FDA Approves Pfizer’s Anti-smoking Drug
Pfizer's new drug, Chantix, which will help cigarette smokers to quit smoking, wins U.S. Food and Drug Administration's approval.

The active ingredient in Chantix is varenicline tartrate. The FDA gave chantix priority review based on the better effectiveness shown in preliminary trials compared to another anti-smoking drug known as zyban. Drugs receiving priority review get approved or rejected within six months while ordianry drugs get evaulated within ten months, reports foodconsumer.org.

Addiction to tobacco smoking is the number one harmful habit in the world. It is notoriously difficult for one to quit smoking since nicotine in the cigarette smoke binds to nicotinic receptors in the brain. These receptors in turn stimulate the reward pathway in brain circuitry. The activation of this pathway gives a pleasurable and contented feeling, which gradually transforms into a vicious cycle of craving and withdrawal.


Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive